| Print
Prelude Therapeutics (PRLD)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approachesto clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novelpayloads.
Address
1201 North Market Street
18th Floor, Post Office Box 1347
Wilmington
DE
USA
19801
Telephone
+1 302 467-1280
Forecast key dates
| Name | Key Date |
|---|---|
| Prelude Therapeutics Inc Fourth Quarter Earnings Results for 2026 | 2027-03-10T00:00:00 |
| Prelude Therapeutics Inc Annual Report for 2026 | 2027-03-10T00:00:00 |
| Prelude Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-12T00:00:00 |
| Prelude Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-14T00:00:00 |
| Prelude Therapeutics Inc Annual General Meeting for 2026 | 2026-06-12T08:30:00 |
| Prelude Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-06T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| The Citizens Life Sciences Conference | 2026-03-10T15:25:00 |
| Prelude Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2026-03-10T00:00:00 |
| Prelude Therapeutics Inc Annual Report for 2025 | 2026-03-10T00:00:00 |
| Prelude Therapeutics Inc Third Quarter Earnings Results for 2025 | 2025-11-12T00:00:00 |
| Prelude Therapeutics Inc Second Quarter Earnings Results for 2025 | 2025-08-14T00:00:00 |
| Prelude Therapeutics Inc Annual General Meeting for 2025 | 2025-06-12T08:30:00 |
| Prelude Therapeutics 46th Annual Goldman Sachs Global Healthcare Conference 2025 | 2025-06-11T09:20:00 |
| Prelude Therapeutics Jefferies Global Healthcare Conference 2025 | 2025-06-05T15:10:00 |
| Prelude Therapeutics Inc First Quarter Earnings Results for 2025 | 2025-05-06T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.